Integrating genomics into prognostic models for AML Journal Article


Authors: Sanchez, M.; Levine, R. L.; Rampal, R.
Article Title: Integrating genomics into prognostic models for AML
Abstract: The use of genomic profiling in acute myeloid leukemia (AML) has led to an improved understanding of disease pathogenesis. Genomic profiling has given rise to fundamental observations about the biology of AML and has served to better define clinical outcomes for patients based on somatic mutational status. As additional mutations are identified with a known or postulated role in AML pathogenesis, the challenge ahead will be learning how to integrate these findings into clinical practice in such a way that they have a meaningful impact on patient care and, ultimately, on patient outcomes. Potential goals include using genomic information for refined risk stratification and clinical decision making, and to identify genetic lesions that guide the use of molecularly targeted therapies. The development of next-generation sequencing technologies has made genomic profiling a viable option for use in clinical practice because it can provide robust, high-coverage sequencing data for multiple genes in 1 assay, within a clinically reasonable time frame. The present article discusses recent candidate gene sequencing studies, the development of prognostic models based on these studies, and the current and potential future uses of next-generation sequencing technologies in making treatment decisions for patients with AML.
Keywords: treatment response; unclassified drug; acute granulocytic leukemia; gene sequence; somatic mutation; cancer patient; cytarabine; molecular genetics; gene frequency; cytogenetics; mutational analysis; tumor marker; cancer genetics; leukemogenesis; daunorubicin; allogeneic hematopoietic stem cell transplantation; 5 aza 2' deoxycytidine; genetic risk; tumor gene; azacitidine; transcription factor runx1; randomized controlled trial (topic); phase 3 clinical trial (topic); cd135 antigen; nucleophosmin; ccaat enhancer binding protein alpha; next generation sequencing; cancer prognosis; protein nras; human; article
Journal Title: Seminars in Hematology
Volume: 51
Issue: 4
ISSN: 0037-1963
Publisher: W.B. Saunders Co-Elsevier Inc.  
Date Published: 2014-10-01
Start Page: 298
End Page: 305
Language: English
DOI: 10.1053/j.seminhematol.2014.08.002
PROVIDER: scopus
PMCID: PMC4236107
PUBMED: 25311742
DOI/URL:
Notes: Export Date: 1 December 2014 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Raajit Kumar Rampal
    338 Rampal
  2. Ross Levine
    775 Levine